-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite considerable progress in targeted therapy for high-risk (del[17p] and/or TP53-mutated) chronic lymphocytic leukemia (CLL) patients, high-risk CLL patients have The prognosis remains relatively poor
.
Combining a variety of drugs with different mechanisms of action may further improve the clinical prognosis of such CLL patients
leukemia
Obinutuzumab (GA-101) is a monoclonal antibody that targets the CD20 antigen on the surface of precursor B cells and mature B lymphocytes
.
Obinutuzumab binds to CD20 to mediate B cell lysis through the involvement of immune
Obinutuzumab (GA-101) immunization
The CLL-GIVe study is an open-label, multicenter clinical trial that enrolled previously untreated patients with CLL with del(17p) and/or TP53 mutations
.
Six cycles of induction therapy with obinutuzumab, ibrutinib, and venetoclax (GIVe) were administered, followed by 6 cycles of consolidation therapy with venetoclax and ibrutinib
Remission rate after the 15th cycle
Remission rate after the 15th cycleBetween September 2016 and August 2018, a total of 41 patients were recruited to receive study treatment, and all 41 patients were included in the efficacy and safety analysis population
.
After the 15th cycle, the complete remission rate was 58.
After the 15th cycle, the complete remission rate was 58.
Progression Free Survival (PFS) and Overall Survival (OS)
Progression Free Survival (PFS) and Overall Survival (OS)The estimated progression-free survival (PFS) and overall survival (OS) rates at 24 months were both 95.
1%
.
All patients experienced adverse events
Estimated progression-free survival (PFS) and overall survival (OS) at 24 months were both 95.
CLL2-GIVe regimen has good efficacy as first-line treatment for high-risk CLL patients, and the safety is controllable CLL2-GIVe regimen has good efficacy as first-line treatment for high-risk CLL patients, and its safety is controllable
Original source:
Original source:Henriette Huber, et al.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
